DaVita Inc. (DVA) Earnings Call Transcript & Summary
February 10, 2022
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us on the call for the fourth quarter, and we're glad you're still following what's happening with the company. This is Jim Gustafson speaking — I serve as Vice President of Investor Relations — and with me on the line are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. Before we go further, keep in mind that we might offer forward-looking statements on this call as defined under federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those factors might lead actual results to diverge materially from what the forward-looking statements describe. If you want more information about those risks and uncertainties, take a look at the earnings press release for the fourth quarter along with our SEC filings — that includes our latest Annual Report on Form 10-K, every quarterly report on Form 10-Q filed afterward, and any later documents we file with the SEC. The information we have right now forms the basis for our forward-looking statements, and we have no intention of, and take on no obligation to, revise those statements, unless the law demands it. We also want to point out that certain non-GAAP financial measures will come up during this call. You can find a reconciliation between those non-GAAP measures and the matching GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThanks, Jim, and thanks to everyone for being here today as we talk about how we did in the fourth quarter and what we're thinking for 2022. Every quarter for the past two years, I've hoped this would be the final occasion the pandemic opens my remarks to you, but COVID keeps changing and directly affecting our world, particularly our healthcare system. Much like what the broader population has experienced, infections among the patients we serve rose sharply from late December into January. When it crested in the second week of January, the count of new cases was over double the peak seen last winter. Thankfully, the death rate so far with this most recent wave has come in below what we saw in earlier waves; for Q4, our estimate of the additional deaths attributable to COVID is roughly 1,100, versus roughly 1,600 in Q3. Even with all the difficulties COVID brings, I remain amazed by how resilient and committed our teammates are throughout the DaVita Village, from those caring directly for patients to those working in corporate roles — everyone keeps pushing with unwavering dedication to deliver high-quality care, adapt to a rapidly shifting environment, and demonstrate tremendous compassion and support for our patients. For the rest of what I have to say, I'll touch on five areas: transplant, the labor market, our supply chain, Integrated Kidney Care, or IKC, and then I'll finish with our fourth quarter results and our outlook. Starting with transplants: at our Capital Markets Day presentation in November, I talked about how we're focused on innovation to enhance the patient experience at each stage of the kidney care journey, from slowing the progression of kidney disease to transplant, and from acute hospital care to dialysis at home or in a center. For most of our patients, transplant is the preferred treatment option. And in 2021, even with the difficulties created by the COVID pandemic, we celebrated nearly 8,000 DaVita patients getting a transplant, which surpassed our pre-pandemic level. That said, getting a transplant is a lengthy and complex process, and the typical wait for an organ runs between four and five years. Remaining active on the waitlist for that long is hard. Consequently, patients occasionally lose their chance for a transplant. We've been trying to tackle some of these issues through our industry-leading transplant smart education program and our partnership with the NKF to help more patients locate living donors. In early January, we announced the acquisition of MedSleuth, whose software allows for closer partnerships and better coordination among transplant centers, nephrologists, and kidney care providers, with all three collaborating to support our patients on their transplant journey. These efforts can also help advance another important goal of ours: improving health equity. A lot of process and outcome results in transplant are quite inequitable, varying by race and ethnicity, economic means, and insurance coverage. Our belief is that it doesn't have to be this way. If we remove obstacles that keep people from getting care, simplify every step, and offer solid coordination and assistance throughout the transplant process, that can help make transplants not only more accessible but fairer for the patients we serve. Let me now turn to what's happening with the labor market. I've had the good fortune to be a member of the DaVita Village for more than two decades, and throughout that period, in the various positions I've held, I have never seen a labor market this difficult. To address this, we've given additional pay and benefits to support our frontline caregivers through COVID; we've also sped up wage increases, concentrating especially on our clinic teammates. As we said before, we anticipate unusually large wage increases during 2022, which will add further pressure on our cost structure in the future; we feel that investing in our people will strengthen our capacity to keep and hold on to the talent required for reaching our long-term goal. Even so, labor markets stay extremely fluid and will keep being a variable that swings results this year. Through the years, especially when the pandemic and natural disasters hit, we've worked through numerous supply chain difficulties. At present, our supply chain has shown itself to be quite resilient. Right now, we are managing a shortage of supplies tied mainly to dialysate, a fluid solution that hemodialysis uses to remove toxins and fluid from the blood. This shortage has spread across the whole kidney care community, and together, as one community, we have joined forces once more to support our dialysis patients, and so far we've managed to deliver uninterrupted life sustaining care. We anticipate these dialysis-related difficulties will stay with us through the second quarter. Moving on to IKC, we now have confirmation regarding the market where we'll work alongside physicians under the federal government's new five years CKCC demonstration; these programs brought in roughly 12,000 <<inaudible>> patients plus another 12,000 CKD patients spanning 11 value-based programs in various markets. We're working with our nephrologist partners to build a personalized care plan for every covered patient and to spot chances to enhance clinical outcomes and reduce costs for each patient. Taking part in these and other programs will more than double how many patients we serve in value-based care arrangement. Given our upfront costs for these programs and the absence of shared savings payment, as we mentioned in November, we still anticipate that our operating loss for 2022 in our US ancillary segments will grow by about 50 million, though it could rise or fall based on how many new arrangements we sign during the year. We feel we are well-positioned going forward and especially to produce positive clinical and financial results in our IKC business over the long term. Let me wrap up now with fourth quarter results in our updated outlook. Even though Omicron created headwinds, the results we posted for the fourth quarter came in a bit above the middle point of the guidance we had revised. That produced an increase in adjusted operating income for the whole year of roughly 3% compared with 2020. Adjusted EPS from continuing operations rose by about 26% versus the prior year, and free cash flow came in above 1.1 billion, most of which we used to give capital back to shareholders. Looking at 2022, our guidance for adjusted operating income is $1.525 billion to $1.675 billion. The middle of that range sits 35 million under what we expected at Capital Markets Day back in November, and the main reason is our refreshed thinking on COVID and labor costs. As we've noted before, 2022 will be a transition year because of certain near-term investments and difficulties we face, yet we remain confident we're positioned well to perform throughout the kidney care continuum in the years ahead. Our view hasn't changed that we can achieve the long-term compounded annual growth in adjusted operating income of 3% to 7% that was laid out at Capital Markets Day. With that, I'll hand things to Joel so he can go through our financial performance and outlook in greater detail.
Joel Ackerman
executiveThank you, Javier. As Javier pointed out, the results we posted for the fourth quarter came in a bit higher than the midpoint of the guidance we had revised. Within our Q4 numbers, there was a net COVID headwind of roughly $80 million — larger than the quarterly impact we saw across the first three quarters of the year — driven mostly by added mortality tied to the Delta surge during Q3 plus certain short-term rises in labor costs; across the full year, the net COVID headwind came to about $200 million. Per Javier's comments, extra deaths caused by COVID during Q4 numbered around 1100, versus roughly 1600 during Q3. Though forecasting additional mortality for 2022 with accuracy is premature at this stage, in light of a notable jump in infections during January, we anticipate that mortality driven by COVID in the first quarter will land at or above the Q4 level. Compared with Q3, US dialysis treatments per day fell by 135, or 0.1%, in Q4. The main pressure came from rising mortality along with more missed treatments stemming from the continuing COVID pandemic. Quarter-over-quarter, US dialysis patient care costs per treatment rose by about $6, largely because of higher wage rates and health benefit expenses. Our Integrated Kidney Care business recorded a bigger operating loss in Q4, chiefly because of favorable prior periods development in our Special Needs Plans that was recognized during Q3, along with higher costs incurred in Q4, including preparation for new value-based care arrangements taking effect in 2022. The adjusted effective tax rate attributable to DaVita came to 16% for Q4 and roughly 22% for the entire year. That adjusted effective tax rate declined quarter-over-quarter, mainly because a state tax matter was favorably resolved during Q4. Lastly, during 2021 we bought back 13.9 million shares of our stock, which lowered our shares outstanding by 11.5% over the year; so far in 2022 we have repurchased another 1.4 million shares; turning now to what lies ahead in 2022. For adjusted OI, our guidance spans $1.525 billion to $1.675 billion, while adjusted EPS guidance sits at $7.50 to $8.50 per share. The midpoint of that OI guidance range lands $35 million under the $1.635 billion figure we talked about at our recent Capital Markets Day, reflecting puts and takes that offset one another. To begin with, we enjoy a tailwind from a higher final Medicare rate update as well as a partial extension of Medicare sequestration relief; even so, headwinds from the recent COVID surge and added wage rate pressure more than cancel that out. At the midpoint of our guidance range, we have baked in these assumptions regarding COVID. Excess patient mortalities attributable to COVID of 6000. Combined with our typical growth drivers, that would produce a total treatment growth range of about 0.5% to 1%. Various COVID-driven costs, such as PPE, should improve year-over-year, and that improvement will be largely offset by revenue lost from Medicare sequestration relief after Q2 2022. Naturally, the upper and lower bounds of the guidance we've given reflect a variety of COVID situations for 2022. Certain scenarios might cause results to land either above or below that range. Beyond COVID, the headwinds I mentioned during the Q3 earnings call and again at our Capital Markets Day are still with us. Just to remind everyone, we anticipate costs tied to DaVita's share of the industry's pushback against the ballot initiative expected in California. Built into our guidance is an extra bump in labor costs of somewhere between $100 million and $125 million beyond what a normal year brings, and that figure sits $50 million above what we shared at Capital Markets Day. Third, we're looking at a year-over-year incremental operating loss somewhere in the range of $50 million, since we keep putting money into expanding our IKC business. And fourth, depreciation on our new clinical IP platform will kick in, which we figure will be roughly $35 million in 2022, starting in Q2. A handful of other points to help frame how we're currently viewing 2022: we believe continuing MA penetration growth beyond historical levels, plus solid control of non-labor patient care costs, will offset a meaningful chunk of these added costs. Our tax rate projection is 25% to 27%, driven by valid expense being non-deductible. On seasonality, keep in mind Q1 carries seasonally heavier payroll taxes along with the usual co-payment and deductible effects. The bulk of what we'll spend on ballot-related matters lands in Q3. Historically, our G&A runs higher in Q4. Beyond 2022, our expectation remains compounded annual OI growth of 3% to 7% against 2021, and compounded annual adjusted EPS growth of 8% to 14% against 2021. Last, we're projecting free cash flow between $850 million and $1.1 billion for 2022. As we said at Capital Markets Day, free cash flow should stay above adjusted net income, though that gap will narrow as time goes on. Operator, please open the call for Q&A.
Javier Rodriguez
executiveHi, Sarah.
Sarah James
analystThank you. Yes, hello; I was hoping to understand, as we move through Omicron and consider the waves still to come, there appear to be outcomes that are milder, as you noted earlier today. And I'm curious whether that's factored in when we look back at your Capital Markets Day, where you mentioned the 160 million to 200 million in OI drag across the next four to seven years stemming from excess mortality. Does that factor in continued milder COVID trends as time passes?
Javier Rodriguez
executiveWell, I'll let Joe address the figures shortly, but let me begin by saying that the way we discuss this within the company is that we will no longer speculate about how it will behave, because we have been taken by surprise so many times. We all felt such optimism when the vaccines arrived and then when the boosters arrived; and naturally, that has led to milder hospitalization and mortality, but ultimately, I believe we can all now agree that nobody can predict where this is headed. Our hope is that it becomes less impactful on our business and eventually becomes something we can handle in the normal course of business, but assuming that would not be prudent. So why don't you go ahead, Joel, and discuss what we've incorporated into the number.
Joel Ackerman
executiveAppreciate that, Sarah. When I consider how the effects of COVID will unfold down the road compared with something like an Omicron wave or a Delta wave, COVID produces a wide range of consequences throughout the P&L. What we have stated, and what still holds, is that plenty of offsets exist in all areas apart from excess mortality, and the net effect we anticipate from COVID is going to be mostly the net effect of excess mortality. With Omicron, what you observe is that although it is indeed a milder illness, its transmissibility was so much greater that it still generated a substantial wave of excess mortality. That showed up in Q4. We keep seeing it in Q1. So when I think about various variants and how they could develop in the future, I believe the bottom-line question is this: what will the effect be on excess mortality.
Sarah James
analystAlso, could you give us an update on those payer discussions — when you discuss upcoming rates, are you factoring in wage inflation? I’m not sure whether that would apply to the ‘24 contracts at this point.
Javier Rodriguez
executiveSure, those talks are happening right now, as we speak. That said, the truth is, as you’re aware and as we’ve discussed for a while, the agreements we have generally run for longer periods. Because of that, most of our contracts aren’t coming up for renegotiation. So naturally, we’ll need to evaluate how inflation trends over time as each individual contract reaches its renewal point. So at this moment, there — let’s say it’s in, and it reflects what was agreed before this acceleration in inflation became apparent.
Sarah James
analystThank you.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveHi there, Justin.
Justin Lake
analystAppreciate it, everybody. Listen; I’d like to cover several items closely. To begin, Joel, you mentioned that Q1 would resemble Q4 when it comes to the mortality drag, looking at it through an OI lens. Could you take us through it once more, and I may have this written down somewhere, but the OI drag broken out by quarter, Q1 through Q4 of 2001.
Joel Ackerman
executiveThe OI drag for each quarter, I’ll give this from memory, it landed in the 30s for both of the first 2 quarters, so mid 30s, 55 in Q3, and 80 in Q4 after that. And people are signaling agreement around me, so I nailed it, correct.
Justin Lake
analystAll right, then 80 is what we have for the first quarter.
Joel Ackerman
executiveHold on, Justin — before you move on, allow me to make this clearer. During the script, my statement was that excess mortality for Q1 would be no smaller than the level observed in Q4, and that relates to mortality. Keep in mind, as far as COVID's impact goes, excess mortality works in a cumulative way. So if another 1,100 deaths or more come in, that gets added on top of what the quarter is already showing. Naturally, other dynamics exist, but if your focus stays just on excess mortality — the dynamic that dominates — that figure should rise somewhat.
Justin Lake
analystUnderstood. So perhaps that 50 to 80 becomes 80 to 110, roughly along those lines, moving up by comparable steps. Is that a fair way to frame it?
Joel Ackerman
executiveThat seems somewhat elevated to me, and I believe it really comes down to a pair of factors. A considerable volume of treatments were skipped during Q4, and that represents a short-lived adverse effect from COVID. We would anticipate that figure declining. Beyond that, certain one-time labor-related elements contributed to the COVID hit in Q4 too.
Justin Lake
analystUnderstood. Please forgive me if this was already covered, but does a figure such as 200 for 2021 exist, and did you provide a figure for 2022 that you believe is factored into guidance?
Joel Ackerman
executiveIt is factored into guidance. When we consider the effects of COVID, for the past seven quarters we have been identifying them on a cumulative basis. The further we move beyond when COVID began, the more difficult it becomes to determine what that cumulative effect amounts to. Regarding the baseline — we are now so distant from it that discussing the cumulative effect is difficult. Therefore, we are treating the COVID included in the numbers as essentially the new normal, the point from which we will proceed going forward. We will keep discussing the effect we observe quarter-over-quarter, but I believe we will stop discussing it as a cumulative figure.
Justin Lake
analystAll right. Then you mentioned Medicare Advantage penetration acting as an offset in this case. Could you share what that figure stood at when the year closed, and where things sit roughly following open enrollment?
Joel Ackerman
executiveSure. As of the year's close — that being the freshest figure I've got, Justin — we stood at 42.3% on MA. And I believe that's the most current one we intend to present to you.
Javier Rodriguez
executiveSure, looking at the full year, I'd say our expectation is that growth stays solid, though it won't be at the same level we witnessed in 2001.
Justin Lake
analystAll right, excellent. Then one final item regarding the dialysate matter. Could you share with us — you mentioned that, and I'm aware there's been some chatter about this within the industry <<inaudible>> evidently has a problem. Are you able to verify, like, the source of where this problem originates? Also, you stated it will persist at minimum through the second quarter, or your belief is it lasts for the second quarter — is there any clarity regarding whether this gets better?
Javier Rodriguez
executiveWell, indeed, the community — for every provider this is a national problem, so supply has been short. One can follow it back, naturally, to the chain supply problems throughout the country, plus the distribution centers and the labor problems; so it's an accumulation of each of those. Thus there was labor, transportation, all of it, everything converged, just as it has occurred in so many locations. What our community did is, naturally, the initial step is bring in the clinical leadership to ensure we were performing safe dialysis, after that we began essentially titrating so that we'd consume a smaller amount of the product, and after that we ensured that everyone grasped what type of inventory existed at every location, so that nobody would pile up or hoard inventory; so the whole community did that. The clarity we currently have is that, once more, that will resolve and we will return to normal at some point in Q2, that's what we're being informed, and so we will stay in the condition where we're all, so to speak, at a considerably reduced inventory level. Does that — did I address your question, Justin?
Justin Lake
analystYeah, thank you. I appreciate that. I’ll get back in the queue.
Javier Rodriguez
executiveNo, no, no. If it were completely obvious regarding this entire idea of why we don’t wish to return to that baseline, because it’s so distant. So, just to highlight something all of us are dealing with, that’s travel and entertainment, which we obviously have, one quarter versus another, you might say we previously had a run rate, as the world truly shifted in travel and entertainment, it’s going to be entirely different. Then we had benefits, about which we informed you we had a run rate, but the benefits have shifted and the run rate; so that’s why it becomes a bit more difficult to delve into that and, as Joel said, we want to move now into what we might call the new normal and proceed from there, so hopefully that was clear here.
Justin Lake
analystGot it. Thanks.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHello there, good afternoon, everyone. I'll go ahead and ask my questions now. If we look more closely at the 2022 OI guidance, it dropped by 35 million. Did I correctly hear that labor expenses are $50 million higher compared with the Analyst Day? On top of that, you're dealing with more COVID — excess mortality than anticipated, and your current assumption is 6000 excess mortality for 2022; that appears to be quite a few headwinds against your guidance of a 35 million reduction, so I just want to grasp which tailwinds existed relative to your earlier guidance.
Javier Rodriguez
executiveYes, Pito, I would highlight two tailwinds. First, the final Medicare fee for service rate ended up at 1.9%, which exceeded what we had estimated, and second, we received partial sequestration relief covering the year, amounting to roughly $25 million; so those balance things out and you end up with a net $35 million decline.
Pito Chickering
analystAll right. Regarding excess mortality, I realize forecasting it right now is not feasible, with roughly 100 during Q1. It’s somewhat ambiguous what the incidence rate looks like for newly entering dialysis patients. So could you possibly provide some detail on the number of patients you had when Q3 ended? What was that count at the close of Q4, and how is it trending around now in Q1?
Javier Rodriguez
executivePito, I’m not certain I follow what you’re asking.
Pito Chickering
analystYeah, so I believe you provided figures on the additional deaths for Q4 and Q1. And I suppose, looking at the flip side, you also have the expansion <<inaudible>> of fresh individuals starting dialysis. So I'm just wondering whether you could share roughly what — how many individuals were there in Q3? What number did you have when Q4 ended, and where does that stand right now during Q1?
Javier Rodriguez
executiveYeah, so the number of patients has stayed fairly level. When it comes to the fundamental factors behind new dialysis admissions, we truly haven't observed any shifts in that area. It keeps following the same trend that existed before COVID, and really there are just two forces at play when you examine treatment count or treatment volumes or treatments per day from Q3 through the close of the year, and those are first, the ongoing additional deaths we mentioned, and second, the factor of skipped treatments. So if your question concerns the pipeline of new dialysis patients, that is still pretty robust.
Pito Chickering
analystAll right. So looking at it a different way, when you compare how the first quarter stacks up against the fourth quarter on a sequential basis — we've already seen those extra deaths, plus that gap in timing across quarters, and on top of that the treatments missed in Q4 because patients were in hospitals — should we assume Q1 comes in slightly below Q4, or roughly flat quarter over quarter?
Javier Rodriguez
executiveMissed treatment rates are going to play a big role there. I'd say, for the — actually, there's another factor: we closed an acquisition during Q4, and it brought in close to 1000 patients, a bit — roughly 750 patients. So that feeds into the picture and gives Q1 a lift too. That said, I'd say across the whole year, we are — using the COVID figures we factored into our forecast, we expect treatment volume to rise somewhere in the range of 0.5% to 1% for the year; clearly, depending on how COVID unfolds, that figure might shift.
Pito Chickering
analystOkay. And next, regarding IKC, I believe during the Analyst Day you provided guidance of roughly 50 million to 75 million in additional costs for 2022. In the script, I think you mentioned 50 million. I simply want to check whether the economic costs for IKC have shifted compared with what was shared at the Analysts Day.
Javier Rodriguez
executiveYeah, I believe that figure has not shifted, Pito, so it is the 50 just to clarify, incremental 50.
Pito Chickering
analystGreat. Then I have another item regarding IKC. If we consider the group of patients you brought in during 2021's first quarter, how did their losses look when you initially acquired them compared with where they stood at the close of 2021's fourth quarter? Can you shed any light on how that patient group's loss has evolved across the year?
Javier Rodriguez
executiveSure, not at this point, Pito. Keep in mind that during year one, we typically generate no revenue; therefore it will genuinely be at some point in 2022 when we begin to observe that flowing through into the financials.
Pito Chickering
analystAll right, and then a couple more very fast ones here. At the close of the fourth quarter, what did your home treatments look like? And how ought that to move along across 2022?
Javier Rodriguez
executiveSure, the rate of penetration for home was within the low 15% range. Over the year, home was up roughly 3%, while in center it declined 2%. So we keep moving forward on expanding home and leading in that modality, and that remains solid; for the coming year, we aren't giving specific guidance on that figure.
Pito Chickering
analystAnd then regarding what Justin asked about the shortage of dialysate supply, could there be any cost pressures from inflation if you need to go to a spot market to obtain the dialysate you need, or do those fall under the contracts? Thanks very much.
Joel Ackerman
executiveYeah, thank you, Pito. Where the dialysate is concerned specifically, it's under contract, so that one is a no.
Pito Chickering
analystGreat, thanks so much.
Joel Ackerman
executiveThank you.
Kevin Fischbeck
analystOkay, great, thank you. I suppose it isn't completely evident to me what signal you're sending regarding the 2023 outlook. I realize it's still far away, but during the previous quarter you provided remarks on how 2023 might shape up. And it appears certain headwinds could carry over into 2023, such as possibly elevated labor expenses or mortality starting from a somewhat higher baseline, yet a tailwind such as the sequestration delay would not; even so, you're also suggesting that your growth rate for 2021 is unchanged. As a matter of fact, 2021 comes in slightly above, which would suggest a somewhat larger 2023 figure. I'm merely attempting to reason directionally—how ought we to frame 2023 relative to what you said previously?
Javier Rodriguez
executiveYes, so here's what I'd say. To begin with, your observation that labor and COVID continue to be major uncertainties throughout 2022 and possibly 2023 is exactly right. With that said, the increase we discussed for 2023, at Capital Markets Day, continues to be something—has remained something—we hold a great deal of confidence in; and were I to group them, I'd say the simpler items we can foresee propelling '23 relative to '22, one would be the ballot initiative disappearing, correct, we don't face those in odd years; second would be IKC beginning to record revenue in 2023 from the sizable cohort of patients being brought on in 2022; third are several cost programs that we possess and are rolling out throughout the P&L; so those are, I'd say, the ones where we enjoy considerable visibility. The one where we enjoy less visibility is the COVID unwind. We keep believing that as COVID recedes into the background going forward, that will serve as a tailwind for us. It'll serve as a tailwind for us on unpredictable cost items but above all, it'll serve as a tailwind for us on patient growth. So our perspectives on those haven't shifted and were I to attach a figure to them, I believe you could sum those up and readily arrive at a $200 million opportunity we are pursuing and that would come on top of the ordinary growth we'd anticipate in a standard year.
Kevin Fischbeck
analystHowever, the way you're currently projecting deaths from COVID seems somewhat elevated. Therefore, my assumption is that this could perhaps push back the point when that $200 million gets used again, which would mean the amount you recover in 2023 ends up smaller than what you'd have expected a few months back?
Javier Rodriguez
executiveWell, timing is going to be the determining factor here, and we don't claim to possess a crystal ball regarding COVID. We aimed to be crystal clear regarding what assumptions went into our forecast, and clearly, things might turn out better, or they might turn out worse. Based on how the timing unfolds during 2022, you get different scenarios for what that figure might be in 2023.
Kevin Fischbeck
analystAll right, that makes sense. Then, for the quarter, it appears you shut down 30 centers, which, as far as I can recall, matches the highest number you've ever closed within a single year — at least across the last decade plus that I've been following DaVita. So I'd like to know what was behind those closures in Q4? I believe the annual figure comes to double anything you'd previously done in a year.
Javier Rodriguez
executiveYeah, I appreciate that question. It's somewhat above the usual level, though we do consistently see a number of center closures and consolidations, and so on. The way I'd suggest framing our footprint is through three lenses. The first, naturally, is patient access — making sure patients are safe and possess the proper access. The second lens concerns the balance between home and in-center, and how that balance shifts as time passes. The third involves utilization, and we've obviously experienced, owing to that excess mortality, a certain drop in utilization. Then finally, there's what you might call the dynamics of each local market. So we aim to be extremely careful and very deliberate — and if you wanted the bottom line, it's that our ongoing expectation is to construct fewer de novos and more home centers as time goes on.
Kevin Fischbeck
analystAll right. But what I’m getting at is, suppose that change — if what you mean is that the COVID-related decline is being made up, then with the low volume you have this year, my take is those locations simply won’t remain open, since they’re going to win that business back. Is the real story more that the move toward home is the main factor behind it, or is it something else?
Javier Rodriguez
executiveWhen you look at how our utilization has moved across time, the fact is we began expanding more slowly before COVID than was the case during COVID. So as that stacks up, our footprint ends up with lower utilization than what we saw in the past; and so we’re simply — and then you factor in the trend of home expanding, and that’s what we’re doing; we only want to ensure the proper modality is in the proper market, and so we keep evaluating that in each market.
Kevin Fischbeck
analystAlright. So perhaps for the final question, regarding the greater labor expenses you're now factoring in compared to what was guided before, do those reflect wage growth that raises the baseline moving ahead, or does part of it come from something else? I believe previously you mentioned more training and that sort of thing. Would any portion of that fall away, or does this 50 million essentially get added to the base going forward?
Joel Ackerman
executiveYeah, that's a fascinating point. We happened to be discussing exactly that, since naturally turnover has picked up somewhat, and we're figuring out ways to make training more efficient and effective, yet most of that figure will remain with us.
Kevin Fischbeck
analystOkay, great. Thanks.
Joel Ackerman
executiveThank you.
Gary Taylor
analystHey there, good evening. I've got a few quick things to ask, and then one bigger item. Regarding what was said about the sequential rise in commercial mix that's unfolding — is the mortality effect still the main thing driving that?
Javier Rodriguez
executiveCorrect; and what stays steady is that patients truly appreciate having the option to hold onto their commercial insurance. That has genuinely shown, via pandemic resilience, how much value the patient places on retaining their coverage, and then the extra deaths are arriving, like you mentioned, from a larger count of Medicare patients.
Gary Taylor
analystThen there's the reference in the release regarding flu vaccine being part of the sequential revenue growth. I realize that's a seasonal item for you folks. Is that — how material is it? And is there any bigger uptick in that this year that matters at all, just given the awareness? Yep.
Javier Rodriguez
executiveOh, sorry. I figured you had finished, Gary. That figure is immaterial, and it's actually offset within the cost line items; so essentially it's a service provided to our patients since it's beneficial and convenient for them, rather than viewing it as an economic one.
Gary Taylor
analystYeah. One final item. I'm curious about your perspective. I have not heard anyone from your team discuss the Supreme Court litigation involving ERISA plans that altered how dialysis payments and the benefits structure work. Oral arguments, I believe, are scheduled for March 1, with a decision likely this summer. My understanding is that your position would be that these are discriminatory practices, and presumably that's what the court will rule on. But what are your thoughts on what it means if the Sixth Circuit gets reversed while the Ninth Circuit is more or less affirmed, giving ERISA plans some latitude, for want of a better phrase, to go after cost containment strategies?
Javier Rodriguez
executiveYeah, I appreciate that question. And it concerns me — it's a tricky one for those who haven't been following the specifics. So perhaps I should just pull it up a bit and walk through the case. At its core — the issue centers on Medicare in the Secondary Payer Act, usually called MSPA, which shields patients from both direct and indirect discrimination. That's essentially the crux of it. More specifically, the question is whether there's a difference between a dialysis patient and what the statute actually says, which is ESRD patients. That may come across as splitting hairs over wording, but it genuinely sits at the center of this. So you ask, how did we arrive here? Could you walk through how we arrived here? Basically, as you're aware, there are small employer groups steered by third-party benefit design that curtailed the benefit for dialysis patients, essentially forcing them onto Medicare in a de facto manner. That then made its way into certain courts, and as you mentioned, the Sixth and Ninth Circuits reached split rulings, after which the Supreme Court indicated it would hear the case; we won't speculate about the outcome, but what you're essentially asking is, fine, what occurs if you do lose — naturally, I draw — my energy comes from winning. But if you ask me what occurs should we lose? There are multiple scenarios, as you know, since the Supreme Court is extremely nuanced, so it could be a narrow holding, which might have zero impact, and they might deliver a great deal of clarity; then you might ask, fine, what occurs if the loss is broader? The first thing is, you'd probably want to put a number on it, and I don't believe I can assist you there, because forecasting what they would intend to do and how they would weigh it against their reputational risk, plus the reality that there are all sorts of legal obligations under the ADA now, is impossible. On top of that, we have a discrimination provision in the ACA. So it's possible that we're contesting one pillar, yet the other two pillars are strong enough that there's actually no impact — but we simply don't know. Our advocacy isn’t going to slow down, and should we come out on the losing end, we’ll keep pursuing a clear answer through the legislative route. What matters most to us, though, is safeguarding our patients, ensuring they can obtain treatment as they would for any other condition. That’s why we’ll stay extremely focused and push forcefully on both the legal and legislative fronts, since we feel our patients are owed that. I’ve said quite a bit, so let me pause there—given how significant this topic is, are there any follow-up questions?
Gary Taylor
analystNo, I believe — what I mean is, clearly, people putting money in want — they're attempting to figure out how to put a number on the chance of a loss, and I'm having a hard time with that too, and I lean toward agreeing, it would be a major leap to assume a lot of plans would alter behavior in a meaningful way. So at this point, I simply value what you've presented there.
Javier Rodriguez
executiveThanks.
Gary Taylor
analystThank you.
Lisa Clive
analystHello. I have two items to ask about. First, what share of the patients you serve who qualify for Medicare are currently enrolled in MA? As I recall, the figure you shared most recently, near the time of your Q3 results, was approximately 41%. Second, regarding labor expenses, would you say this is mostly driven by wage inflation, or does it also involve staffing shortages — could you clarify how those two components break down?
Javier Rodriguez
executiveSure, briefly: when it comes to MA, slightly more than 42% of all our Medicare patients are in MA plans. As for labor, what we are generally referring to is wage inflation.
Lisa Clive
analystAlright, so you're not sitting on many open positions, and you're not relying on temp agencies much, is that right?
Javier Rodriguez
executiveActually we are, but we handle it fairly well since it tends to be brief. So I'd say we're trying to respond in the most supportive way possible, like you mentioned, asking whether this serves as a solid bridge toward what comes next, and the truth is it does, despite the pressure we're under. There's something we do whenever staffing gets tight: occasionally our leadership team, who are on salaried pay, will jump in on the floor, since many of our facility administrators happen to be nurses. We don't want that arrangement lasting forever — it can't be sustained — yet it makes a real difference when you're shorthanded. So there are many moving parts, as you're aware, and lots of interactions to weigh when it comes to staffing, but if you asked me what makes up the biggest share of that figure, it's wage inflation.
Lisa Clive
analystAll right, excellent. And then a final item regarding home dialysis — in what way has the rate of growth shifted, if it has at all, across the past 1 or 2 years? My sense is there could be greater appetite for it, though do you additionally face additional constraints when it comes to getting patients trained, given that staff are stretched thin? It would help to know how that is developing.
Javier Rodriguez
executiveYes, I'd say COVID naturally introduces certain air pockets when it comes to growth, and we've discussed excess mortality quite a bit during this call. If you step back and examine the overall mix, across the past 2 years, essentially we moved from slightly above 12% to 15% of our patients on some form of home modality. That modality produced double-digit growth for a considerable stretch, and then COVID hit. What took place through the year was that we saw growth between 2% and 3%, yet at the same time our in-center volume contracted. The modality therefore remains strong, patients keep choosing it, we keep building the finest home suite available, wrapping patients in every kind of support so they can move onto the modality. Regarding training, naturally COVID brought certain difficulties, and COVID also delivered a bit of a tailwind, since people think, wow, if this occurs once more, perhaps I'd prefer to dialyze at home. It's still not a simple answer, but ideally those patterns give you a feel for the demand for the modality.
Lisa Clive
analystGreat, thanks very much.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHi everyone, and thanks for letting me squeeze in one final follow-up. This will be very brief, and I realize you can’t really model excess COVID mortality stemming from COVID, since predicting it is essentially not possible. That said, could you share some sensitivities regarding the effect on operating income if excess mortality comes in at 3,000 rather than the 6,000 you’re assuming?
Javier Rodriguez
executiveDoing the rough math, that would come to roughly a $30 million difference.
Pito Chickering
analystSo in essence —
Javier Rodriguez
executiveAnd that applies to the full year, and a mid-year convention is what’s used there.
Pito Chickering
analystYeah. So looking at that another way, if you hadn't absorbed as much as 6,000 in extra COVID deaths, that alone would have accounted for nearly the entire gap between the outlook you gave at the Analyst Day and the one today.
Javier Rodriguez
executiveYes, Pito, I believe that arithmetic checks out.
Pito Chickering
analystOkay. Thanks so much, guys.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveOkay, thanks, Michelle, and I appreciate everyone taking an interest in what we do. As you’re able to tell, the near term is difficult, just as it is for a lot of other businesses, since the macroeconomic picture is pretty complicated and shifting, especially when it comes to labor markets. Even so, I hope our voices make it clear that over the long run, we keep developing a distinctive set of capabilities, and we feel very good about where we stand to provide integrated care to our patients, achieve world-class outcomes, and generate savings for our payers. I’d be leaving something out if I didn’t close by noting that none of this would happen without the resilience, the passion, and the commitment of the DaVita team, which gets up each and every day to provide life sustaining therapy. So I’m grateful for your time, and we’ll speak again in the next quarter. Take care.
Operator
operatorThanks. That wraps up the conference call for today. At this point, feel free to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.